# A Phase 1 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in Chronic Hepatitis B Patients

> **NCT02569372** · PHASE1 · COMPLETED · sponsor: **Green Cross Corporation** · enrollment: 53 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **BIOLOGICAL:** GC1102

## Key facts

- **NCT ID:** NCT02569372
- **Lead sponsor:** Green Cross Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-09
- **Primary completion:** 2017-10-12
- **Final completion:** 2017-10-12
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2017-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02569372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02569372, "A Phase 1 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in Chronic Hepatitis B Patients". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02569372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*